The drug called torrent has been on the market for years, but is now being tested on patients in the United States.

In a study published last month in the journal Science Translational Medicine, researchers at Johns Hopkins University found that the drug killed more than one in three patients who received it.

The study included more than 700 patients with lung cancer who received a dose of the drug at Johns’ Johns Hopkins hospital.

Researchers say the drug’s effects could be long-lasting, but only if the patient does not stop taking it within a few days of starting treatment.

“This is the first time we’ve been able to demonstrate that this drug can kill cancer cells in the tumor,” lead researcher Dr. Daniel Fuhrmann, a professor of surgery at Johns, said in a statement.

“We are hopeful that this discovery will help us improve the safety and efficacy of this drug.”

The drug was first approved in Europe in 2013.

Fuhlmann says he’s not certain if other countries are testing the drug on their patients, but he thinks that will happen as soon as the study is completed.

“I would expect the number of countries who will approve this drug to be increasing,” he said.

“The other thing I would hope is that people in the US who are not on this drug, and are not looking for a drug, would take it, because they are going to be the ones dying.”

Fuhrlmann and his team have also tested a smaller version of the compound.

The drug they found to kill cancer-causing cells was also tested on a patient who received its second dose, but the researchers say the results of that trial were inconclusive.

The results are still being analyzed.

According to the Johns Hopkins team, the drug has been shown to work by targeting an enzyme called the COX-2 receptor.

The COX enzyme is a protein that helps to make the molecules that make cancer cells grow.

The researchers say that they hope to find a better way to make drugs that target COX enzymes, and so they’re currently working on a second version of torrent that targets a different part of the enzyme.

The drugs researchers are using for their research include two that were approved in the U.S. last year, the non-steroidal anti-inflammatory drug metformin and the anti-infective drug diclofenac.

Both drugs are approved for the treatment of certain cancers.

Both are approved by the Food and Drug Administration.

The FDA says that the compounds have not been tested on human patients, so there is no way to know whether or not they will work in patients with breast cancer or any other cancer.

But the agency says that it will be studying the drug for possible safety.